

**Question for written answer E-004281/2021
to the Commission**

Rule 138

Ernő Schaller-Baross (NI)

Subject: Pharmaceutical companies raising EU COVID-19 vaccine prices

The Delta variant of the SARS-CoV-2 virus is the globally dominant strain and has already been identified in almost all European countries. As Member States in vulnerable positions try to reinforce efforts to prevent the transmission of this highly contagious variant, including through providing additional booster vaccines to their citizens, both Pfizer and Moderna are raising the price of their vaccines in Europe. The Commission has apparently not been effective in combating the pricing policies of these pharmaceutical companies and has agreed to pay the higher prices.

1. Do the previously concluded contracts with Pfizer and Moderna allow them to unilaterally increase prices?
2. How much has the price of EU vaccine purchases increased as a result of Pfizer's and Moderna's demand for higher prices?
3. What efforts has the Commission made during the bargaining process to counteract the price-raising efforts of the pharmaceutical companies?